Related Experiment Video

Updated: Mar 10, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Patient-reported outcomes in TALAPRO-2 trial: addressing data integrity and comparative clinical benefit in mCRPC

Nobuaki Matsubara1

  • 1Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Chinese Clinical Oncology
|March 9, 2026
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Patient-reported outcomes (PROs)metastatic castration-resistant prostate cancer (mCRPC)poly ADP-ribose polymerase inhibitor (PARP inhibitor)time to definitive deterioration (TDE)

More Related Videos

Focal Laser Ablation of Prostate Cancer: An Office Procedure11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

8.6K
Retzius-Sparing Robot-Assisted Radical Prostatectomy12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

9.7K

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
808